2D-quantitative structure–activity relationships model using PLS method for anti-malarial activities of anti-haemozoin compounds

Phuong Thuy Viet Nguyen1*, Truong Van Dat1, Shusaku Mizukami2,3, Duy Le Hoang Nguyen1, Farhana Mosaddeque2, Son Ngoc Kim1, Duy Hoang Bao Nguyen1, Oanh Thi Dinh1, Tu Linh Vo1, Giang Le Tra Nguyen1, Cuong Quoc Duong1, Satoshi Mizuta4, Dao Ngoc Hien Tam5, M. Phuong Truong6, Nguyen Tien Huy7* and Kenji Hirayama2*

Abstract

Background: Emergence of cross-resistance to current anti-malarial drugs has led to an urgent need for identification of potential compounds with novel modes of action and anti-malarial activity against the resistant strains. One of the most promising therapeutic targets of anti-malarial agents related to food vacuole of malaria parasite is haemozoin, a product formed by the parasite through haemoglobin degradation.

Methods: With this in mind, this study developed two-dimensional-quantitative structure–activity relationships (QSAR) models of a series of 21 haemozoin inhibitors to explore the useful physicochemical parameters of the active compounds for estimation of anti-malarial activities. The 2D-QSAR model with good statistical quality using partial least square method was generated after removing the outliers.

Results: Five two-dimensional descriptors of the training set were selected: atom count (a_ICM); adjacency and distance matrix descriptor (GCUT_SLOGP_2: the third GCUT descriptor using atomic contribution to logP); average total charge sum (h_pavgQ) in pKa prediction (pH = 7); a very low negative partial charge, including aromatic carbons which have a heteroatom-substitution in “ortho” position (PEOE_VSA-0) and molecular descriptor (rsynth: estimating the synthesizability of molecules as the fraction of heavy atoms that can be traced back to starting material fragments resulting from retrosynthetic rules), respectively. The model suggests that the anti-malarial activity of haemozoin inhibitors increases with molecules that have higher average total charge sum in pKa prediction (pH = 7). QSAR model also highlights that the descriptor using atomic contribution to logP or the distance matrix descriptor (GCUT_SLOGP_2), and structural component of the molecules, including topological descriptors does make for better anti-malarial activity.
Background
Malaria is a deadly infectious disease with about 228 million infected cases and 405,000 deaths worldwide, as recorded in 2018 [1]. The disease is caused by the bite of a mosquito having the Plasmodium parasite, which consists of five main species, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium knowlesi and Plasmodium malariae [2]. Of these species, 90% of deaths (mostly in children) were related to P. falciparum [3]. Anti-malarial drugs, such as quinine, chloroquine, artemisinin, proguanil, pyrimethamine, melqloquine, and atovaquone, have been indicated as malaria treatment [4–6]. However, Plasmodium species developed resistance to most of these commonly used drugs. This resistance and the lack of a vaccine has become a major problem in malarial treatment in recent years [7]. Therefore, there is a pressing need to improve the efficiency by modifying existing compounds to face drug-resistance, as well as to discover novel anti-malarial compounds.

Due to funding investment constraints, in silico and collaborative approaches have become particularly attractive approaches for malaria drug discovery efforts. Some in silico techniques, namely molecular docking, pharmacophore models or quantitative structure–activity relationships (QSARs) significantly reduce the time and cost in the drug discovery process. Among the techniques, QSAR is considered a valuable tool that is applied extensively in rational drug design. The predictive QSAR model provides a mathematical correlation between the structural properties of the compounds and their anti-malarial activities using one-, two-, and three-dimensional descriptors of physicochemical properties, as well as structural characteristics relating to the activity. Once a reliable QSAR model has been developed, the biological activities of molecules can be predicted from the molecular descriptors by different methodologies, such as multiple linear regression (MLR), partial least squares (PLS), artificial neural networks (ANN) and heuristic method (HM). In recent years, QSAR models were applied to a variety of anti-malarial compounds to figure out physicochemical and structural characteristics that are essential for their activity [8–13]. Some QSAR models developed using sulfonamide and its derivatives, 5-(2-methylbenzimidazol-1-yl)-N-alklythiophene-2-carboxamid derivatives in order to select models that had the best predicting ability [6, 14]. Other studies used three-dimensional QSAR (3D-QSAR) combining with extra analysis gave striking structural characteristics that related to anti-malarial efficacy and the mechanism of action of anti-malarial compounds [15–17].

The anti-malarial activities of various groups of compounds, in particular quinine and its derivatives, had a satisfactory correlation with their anti-haemozoin activity [18]. Haemozoin is formed inside the food vacuoles of parasites to prevent lethal toxicity of haem, which is a product of the catabolism of haemoglobin. Thus, anti-haemozoin is an important therapeutic target in anti-malarial treatment. Recently, different approaches were highlighted. These approaches include the high-throughput screening (HTS) of anti-malarial drugs based on their physicochemical properties of haemozoin formation, or building computational models for in silico screen novel anti-malarial drugs, or analog development from natural compounds or existing agents [19]. Of which, prediction models of correlation between anti-haemozoin and anti-malarial activities strongly assist in anti-malarial drug discovery, from modifying known compounds to identifying new chemical scaffolds for different targets of a large diverse database of compounds [18]. However, there is no QSAR model for anti-malarial activity of anti-haemozoin inhibitors. The aim of this study was to develop quantitative structure–activity relationship models to determine the influences of physicochemical structures of haemozoin inhibitors on anti-malarial activities.

Methods
The best QSAR model will be chosen and could be applied for screening and designing better anti-haemozoin compounds for anti-malarial activities in next studies. QSAR modelling was conducted for anti-malarial activities of haemozoin inhibitors using the multiple linear regression (MLR) and partial least square (PLS) methods. Database of 21 compounds possessing both anti-malarial and anti-haemozoin activities were used for building QSAR models. The IC50 of these compounds varied from 0.06 – 10.5 µM (or pIC50 ranged between -1.02 to 1.22). The QSAR model was chosen based on the predicted fitness plots and statistical values of the models. Evaluation of QSAR models depended on three data sets, the training, validation and test sets. The results included the corresponding descriptors (coefficients) and correlation of the observed—predicted values of...
anti-malarial activities and the statistical parameters. The parameters, correlation coefficient or coefficient of determination (R² or r-squared), cross-validated r² (or Q²) and r² for the external test set (R²_pred), and root mean square error (RMSE) as fitting criteria, were employed to evaluate the goodness of the models. The predictive model was tested based on different methods, such as internal for training set and external validation for test set, as well as Y-randomization method.

Data set
To perform 2D-QSAR, a complete data set containing 21 anti-haemozoin compounds (Table 1) was taken from the experimental anti-malarial activities identified in a previous work [20]. The half maximal inhibitory concentration (IC₅₀) of the anti-haemozoin compounds was converted to logarithmic scale (pIC₅₀) and used as the dependent variable. These compounds were randomly divided into two subsets, a training set (16 compounds) and a test set (6 compounds).

2D-QSAR
A flowchart for developing 2D-QSAR was conducted following eight steps (Fig. 1). Initially, database included 21 compounds having anti-Plasmodium 3D7A activity. The IC₅₀ values of these compounds were converted into logarithm scale logIC₅₀ or pIC₅₀ (pIC₅₀ = − logIC₅₀). The process of energy minimization of the compounds was performed using MOE 2015.10. A further step was the calculation of 2D descriptors. A total of 206 descriptors described molecular structures, including geometrical, physicochemical, sterical and lipophilic, which were calculated using Descriptors tool in MOE 2015.10. The database was subsequently divided into two subsets, a training set and a test set, with a 75:25 ratio. The database was divided randomly using RAND or Diverse subset using MOE. Selection of descriptors was carried out carefully. Some descriptors were removed based on three methods, firstly, if more than 15% compounds had descriptor values of 0 using Microsoft Excel. Secondly, using Rapidminer Studio 8.2.0 to take out of descriptors of the compounds which possess 50% similarity. Thirdly, remove randomly one of two descriptors having a cross correlation value of more than 70% using Rapidminer. These selected descriptors were also separated according the ratios of between 0 to 1 using Normalize in Rapidminer Studio based on the Eq. 1 below.

\[ X_n = \frac{X_0 - \text{Min}_0}{\text{Min}_0 - \text{Min}_0} \]  

(1)

of which: \( X_n \): Value; \( X_0 \): Initial value; \( \text{Min}_0, \text{Max}_0 \): Minimum, maximum of initial values.

Results and discussion
To conduct this study, database of 21 anti-haemozoin compounds (Table 1) was taken for building 2D-QSAR models to explore the structure–activity relationship of haemozoin inhibitors acting as anti-malarial agents. These compounds had in vitro anti-malarial activities against P. falciparum 3D7A and were used for QSAR modelling. The data set was randomly split into a training set (15 compounds) for model construction and test set (6 compounds), for validation of the model, respectively. The quality of a built QSAR model was demonstrated by the fitting and its predicting ability.

Variable selection
Five two-dimensional descriptors of the training set were selected for QSAR modelling as they all had low inter-correlation (Table 2). They included atom count (aLCM); + adjacency and distance matrix descriptor (GCUT_SLOGP_2; the third GCUT descriptor using atomic contribution to logP (using the Wildman and Crippen SlogP method) instead of partial charge); average total charge sum (h_pavgQ) in pKa prediction (pH=7); a very low negative partial charge, including aromatic carbons which have a heteroatom-substitution in “ortho”
| No | Compound | Structure | Anti-malarial activity (3D7A) IC50 (mM) ± SD | Anti-haemozoin activity IC50 (mM) |
|----|----------|-----------|---------------------------------------------|----------------------------------|
| C1 |          | ![Structure C1](image) | 0.06 ± 42.98 | 42.98 |
| C2 |          | ![Structure C2](image) | 0.56 ± 0.27 | 18.3 |
| C3 |          | ![Structure C3](image) | 1.01 ± 0.50 | 25.96 |
| C4 |          | ![Structure C4](image) | 1.54 ± 0.07 | 53.44 |
| C5 |          | ![Structure C5](image) | 3.06 ± 1.30 | 110 |
| C6 |          | ![Structure C6](image) | 4.80 ± 1.70 | 198.1 |
| C7 |          | ![Structure C7](image) | 6.80 ± 4.40 | 29.04 |
| C8 |          | ![Structure C8](image) | 7.00 ± 1.40 | 43.98 |
| No | Compound | Structure | Anti-malarial activity (3D7A) IC₅₀ (mM) ± SD | Anti-haemoglobin activity IC₅₀ (mM) |
|----|----------|----------|------------------------------------------|----------------------------------|
| C9 |          | ![Structure C9](image) | 8.00 4.58 | 4.58 |
| C10|          | ![Structure C10](image) | 8.00 ± 2.80 | 156 |
| C11|          | ![Structure C11](image) | 8.15 ± 2.60 | 34.67 |
| C12|          | ![Structure C12](image) | 8.95 ± 1.30 | 103.5 |
| C13|          | ![Structure C13](image) | 9.00 ± 1.40 | 14.01 |
| C14|          | ![Structure C14](image) | 9.00 | 36.16 |
| C15|          | ![Structure C15](image) | 9.00 | 160 |
position (PEOE_VSA-0) and molecular descriptor (rsynth: estimating the synthesizability of molecules as the fraction of heavy atoms that can be traced back to starting material fragments resulting from retrosynthetic rules). The study demonstrated that the average total charge sum ($h_{\text{pavg}Q}$) in pKa prediction ($\text{pH}=7$) was the most important descriptor with the correlation coefficient values of about 0.41 (Table 2).

### QSAR model development

After selecting molecular descriptors, the linear QSAR models were built using the training set data. The outliers were checked and removed based on their values of PCA (principal component analysis), Z-score, and ZX-score of more than 2. There are four QSAR models that were developed based on the selection of different methods, namely PLS (Partial least squares) and PCR (Principal component regression), respectively with or without outliers (Table 3).

### Validation of QSAR models

The evaluation of the QSAR models included the internal and external validations. The parameters for internal validation were $R^2$ (a correlation coefficient), $Q^2$ (predictive ability of the built QSAR models in the training set data employing leave-one-out (LOO) cross-validation method), and $R^2_{\text{pred}}$ (predictive ability for the test set). QSAR model is selected if it complies with the three

| No | Compound | Structure | Anti-malarial activity (3D7A) IC$_{50}$ (mM) ± SD | Anti-haemozoin activity IC$_{50}$ (mM) |
|----|----------|-----------|-----------------------------------------------|-------------------------------------|
| C16 | ![Structure](image1.png) | 9.26±1.80 | 30.69 |
| C17 | ![Structure](image2.png) | 9.28±2.40 | 28.5 |
| C18 | ![Structure](image3.png) | 9.50±0.70 | 24.72 |
| C19 | ![Structure](image4.png) | 10.00±1.40 | 41.18 |
| C20 | ![Structure](image5.png) | 10.00 | 38.54 |
| C21 | ![Structure](image6.png) | 10.50±2.10 | 87.76 |

IC$_{50}$ half maximal inhibitory concentration
criteria: the values of the high correlation coefficient \( R^2 \) between the experimental and the predicted values, the predictive ability of the model for the training set \( Q^2 > 0.5 \), and the low standard deviation (RMSE). The comparison of four generated 2D-QSAR models were evaluated and compared in Table 3. The results showed that the QSAR models gave similar evaluation results by using PLS or PCR methods with outliers. This means that using different methods for the whole training dataset did not affect the development of the QSAR models. However, after removing outliers, the PLS model gave the better results, and the PCR model without outliers was worst than the others (Table 3). Therefore, the best QSAR model was the PLS model without outliers. The regression equation is represented as following:

\[
pIC_{50} = -4.90988 + 1.98542 \times a_{\text{ICM}} + 0.74756 \times \text{GCUT\_SLOGP\_2} + 0.59815 \times h_{pavQ} + 0.00837 \times \text{PEOE\_VSA-0} - 0 - 0.12277 \times \text{rsynth}
\]

where: \( R^2 = 0.745031 \), \( \text{RMSE} = 0.166261 \), \( Q^2 = 0.316410 \), and \( R^2_{\text{pred}} = 0.9554 \).

The high values of \( R^2 = 0.745 \); low standard error \( \text{RMSE} = 0.166 \) and the good predictive ability: \( R^2_{\text{pred}} = 0.9554 \) (for the test set) indicated suitability of the model for predicting the anti-malarial activities of other haemoglobin inhibitors from the existing anti-haemoglobin compounds (Table 3). The experimental or observed versus predicted amounts of \( pIC_{50} \) of haemoglobin inhibitors as anti-malarial structures against 3D7A strain were presented in Table 4 and Fig. 1. As can be seen in the Table 4, the predicted values of \( pIC_{50} \) values
### Table 3  Evaluation results of 2D-QSAR models generated by PLS (Partial least squares) and PCR (Principal component regression) methods

| Model 1 (PLS) | Model 2 (PCR) |
|---------------|---------------|
| **With outliers** | **Without outliers** | **With outliers** | **Without outliers** |
| **Regression equation** | **Regression equation** | **Regression equation** | **Regression equation** |
| $pIC_{50} = 0.04406 - 1.17564 \times a_{ICM} + 4.80603 \times GCUT_2 + 0.46880 \times h_{pavgQ} + 0.00334 \times PEOE_{VSA-0} + 0.29021 \times rsynth$ | $pIC_{50} = -4.90988 + 1.98542 \times a_{ICM} + 0.74756 \times GCUT_2 + 0.59815 \times h_{pavgQ} + 0.00837 \times PEOE_{VSA-0} - 0.12277 \times rsynth$ | $pIC_{50} = 0.04406 - 1.17564 \times a_{ICM} + 4.80603 \times GCUT_2 + 0.46880 \times h_{pavgQ} + 0.00334 \times PEOE_{VSA-0} + 0.29021 \times rsynth$ | $pIC_{50} = -4.9556 + 2.02008 \times a_{ICM} + 0.19451 \times GCUT_2 + 0.56938 \times h_{pavgQ} + 0.00850 \times PEOE_{VSA-0} - 0.01478 \times rsynth$ |
| **R²** | 0.587642 | 0.745031 | 0.587642 | 0.738223 |
| **RMSE** | 0.392729 | 0.166261 | 0.392729 | 0.168465 |
| **Q²** | 0.025752 | 0.316410 | 0.025752 | 0.317759 |
| **R²_pred** | 0.773600 | 0.955400 | 0.773600 | 0.954200 |
| No | Compound identification | Structure | Antimala IC₅₀ (mM) ± SD | Anti-hemIC₅₀ (mM) | Experimental pIC₅₀ | Predicted pIC₅₀ | a_ICM | GCUT_SLOGP_2 | h_pavgQ | PEOE_VSA-0 | Rsynth |
|----|--------------------------|-----------|--------------------------|-------------------|------------------|-----------------|-------|--------------|--------|-------------|--------|
| 1  | C₁**                     | ![](image1) | 0.06 ± 42.98             | 1.2185            | −0.006          | 1.53764        | 0.22929 | 1.98287      | 70.91325 | 0.81250     |
| 2  | C₂**                     | ![](image2) | 0.56 ± 0.27              | 0.25181           | −1.573          | 1.48663        | 0.17043 | 0.03097      | 36.76471 | 0.55555     |
| 3  | C₃                       | ![](image3) | 1.01 ± 0.50              | 25.96             | 0.00432        | −0.256         | 1.71097 | 0.13338      | 98.6667 | 0.66666     |
| 4  | C₄                       | ![](image4) | 1.54 ± 0.07              | 53.44             | −0.18752       | −0.303         | 1.50003 | 0.14600      | 98.813 | 123.27970   | 0.84000 |
| 5  | C₅                       | ![](image5) | 3.06 ± 1.30              | 110               | −0.48572       | −0.382         | 1.70074 | 0.16534      | −0.00275 | 129.77250   | 0.46154 |
| 6  | C₆                       | ![](image6) | 4.80 ± 1.70              | 198.1             | −0.68124       | −0.804         | 1.64727 | 0.05872      | 79.449 | 43.25748    | 0.37037 |
| 7  | C₇                       | ![](image7) | 6.80 ± 4.40              | 29.04             | −0.83251       | −0.767         | 1.68854 | 0.18846      | 78.682 | 33.21112    | 0.80769 |
| No | Compound identification | Structure | Antimala IC_{50} (mM) ± SD | Anti-hemIC_{50} (mM) | Experimental pIC_{50} | Predicted pIC_{50} | a_ICM | GCUT_SLOGP_2 | h_pavgQ | PEOE_VSA-0 | Rsynth |
|----|-------------------------|-----------|------------------------------|-----------------------|----------------------|----------------------|--------|--------------|---------|-------------|--------|
| 8. | C8                     | 7.00 ± 1.40 | 43.98                       | -0.84510              | -0.840               | 1.62957             | 0.13516 | 0.00209      | 98.03923 | 0.71875     |
| 9. | C9                     | 8.00       | 4.58                        | -0.90309              | -1.007               | 1.88074             | 0.19433 | -0.55864     | 49.01962 | 0.42857     |
| 10. | C10*                  | 8.00 ± 2.80 | 156                         | -0.90309              | -0.994               | 1.71613             | 0.13718 | 0.00000      | 51.22816 | 0.18518     |
| 11. | C11*                  | 8.15 ± 2.60 | 34.67                       | -0.91116              | -1.509               | 1.61260             | 0.13754 | 0.00052      | 24.50981 | 0.88889     |
| 12. | C12**                 | 8.95 ± 1.30 | 103.5                       | -0.95182              | -1.481               | 1.38153             | 0.15146 | 0.25559      | 58.58442 | 0.57143     |
| No. | Compound identification | Structure | Antimala IC₅₀ (mM) ± SD | Anti-hemIC₅₀ (mM) | Experimental pIC₅₀ | Predicted pIC₅₀ | a_ICM | GCUT_SLOGP_2 | h_pavgQ | PEOE_VSA-0 | Rsynth |
|-----|------------------------|-----------|-------------------------|-------------------|-------------------|-----------------|-------|--------------|---------|------------|--------|
| 13. | C13                    |           | 9.00 ± 1.40             | 14.01             | −0.95424          | −0.760          | 1.79430 | 0.13340      | 0.18358  | 57.32159   | 0.83333 |
| 14. | C14*                   |           | 9.00 ± 1.80             | 36.16             | −0.95424          | −1.180          | 1.58409 | 0.15569      | 0.01251  | 65.69160   | 0.72727 |
| 15. | C15                    |           | 9.00 ± 1.60             | 160               | −0.95424          | −0.608          | 1.66637 | 0.08536      | 0.93749  | 51.42806   | 0.50000 |
| 16. | C16**                  |           | 9.26 ± 1.80             | 30.69             | −0.96661          | −0.415          | 1.85538 | 0.21564      | 0.96585  | 12.25490   | 0.25000 |
| 17. | C17*                   |           | 9.28 ± 2.40             | 28.5              | −0.96755          | −0.968          | 1.66447 | 0.16562      | 0.17235  | 61.27452   | 0.83333 |
| 18. | C18*                   |           | 9.50 ± 0.70             | 24.72             | −0.97772          | −1.291          | 1.59500 | 0.17886      | 0.07861  | 37.01379   | 0.31250 |
| No | Compound identification | Antimal IC₅₀ (mM) ± SD | Anti-hemIC₅₀ (mM) | Experimental pIC₅₀ | Predicted pIC₅₀ | a_ICM | GCUT_SLOGP_2 | h_pavgQ | PEOE_VSA-0 | Rsynth |
|----|--------------------------|------------------------|-------------------|-------------------|-------------------|-------|--------------|---------|-------------|--------|
| 19 | C19                      | 10.00 ± 1.40           | 41.18             | -1.0000           | -1.164           | 1.76194 | 0.05321      | 24.50981 | 0.73913     |        |
|    | ![Structure C19](image)   |                       |                   |                   |                   |       |              |         |             |        |
| 20 | C20*                     | 10.00                  | 38.54             | -1.0000           | -1.298           | 1.66327 | 0.08231      | 27.65577 | 0.36364     |        |
|    | ![Structure C20*](image)  |                       |                   |                   |                   |       |              |         |             |        |
| 21 | C21                      | 10.50 ± 2.10           | 87.76             | -1.02119          | -0.979           | 1.64467 | 0.00702      | 70.19921 | 0.40000     |        |
|    | ![Structure C21](image)   |                       |                   |                   |                   |       |              |         |             |        |

* Compounds belong to test set
**Outlier compounds
were in good agreement with the values of experimental pIC$_{50}$.

The linear graphical plot was depicted in Fig. 2. The graph illustrated the good overlap of the observed and predicted activities of the data set with the high of correlation coefficient of $R^2 = 0.9554$ (Fig. 2). The predicted values of pIC$_{50}$ varied between $-1.021$ to $1.222$ with the value ranges of the selected descriptors presented in Table 5. The decrease of these descriptors led a decrease of pIC$_{50}$ values meaning the increase of IC$_{50}$ which is a decrease of anti-malarial activities.

**Interpretation of descriptors**

It was clearly inferred that the average total charge sum (h$_{pavgQ}$) in pKa prediction (pH = 7) contributed the most to the values of pIC$_{50}$, which could be used as one indicator for predicting anti-malarial activities of other anti-haemozoin agents. The higher average total charge sum (h$_{pavgQ}$) in pKa prediction (pH = 7) resulted in increasing values of pIC$_{50}$ or decreasing of IC$_{50}$ indicating better anti-malarial activities (Table 4). The positive sign of these descriptors indicated that the larger the value of pIC$_{50}$ the lower IC$_{50}$ of the compound. In addition, this feature was also taken for evaluation and prediction of anti-malarial activities for some anti-malarial drugs, such as quinine, pyrimethamine, halofantrine and mefloquine. It was found that the higher their calculated h$_{pavgQ}$ values, the better anti-malarial activities.

Furthermore, the decrease of distance matrix descriptor (GCUT_SLOGP_2) or the third GCUT descriptor using atomic contribution to logP could lead better anti-malarial activity. The result was compatible with the previous study as this descriptor represents for lipophilicity and low lipophilicity, especially at pH 3, 4, and 5 were significantly related to better anti-malarial activity of anti-haemozoin molecules.

In addition, the positive sign of the PEOE_VSA-0 descriptor, a very low negative partial charge, including aromatic carbons which have a heteroatom-substitution in “ortho” position suggests that increasing in the PEOE_VSA-0 will decrease the inhibitory potency of

![Fig. 2 Plot of the correlation between the experimental pIC$_{50}$ and the pIC$_{50}$ predicted anti-malarial activities using partial least squares model](image-url)

**Table 5 Values ranges of selected descriptors in 2D-QSAR model**

| a_ICM | GCUT_SLOGP_2 | h_pavQ | PEOE_VSA-0 | rsynth |
|-------|-------------|--------|-----------|--------|
| Min   | 1.500031    | 0.058723 | -0.558641 | 24.509808 | 0.370370 |
| Max   | 1.880740    | 0.194329 | 0.988134  | 129.772461 | 0.839999 |
anti-haemozoin compounds. The increase of atom count (a_ICM), topological descriptors or structural components of the molecules have an effect on the variation of anti-malarial inhibitory activity of the anti-haemozoin compounds. Moreover, molecular descriptor (rsynth: estimating the synthesizability of molecules as the fraction of heavy atoms that can be traced back to starting material fragments resulting from retrosynthetic rules) was the least contributive. In addition, the predicted $pIC_{50}$ in Table 4 were much different with the experimental $pIC_{50}$ values for the outliers, especially C1, C2, C12, C16. As a result, removing these outlier compounds from the training set for building QSAR model was essential.

The limitation of this study is the toxicity evaluation. In fact, there is no model predicting both the structure–activity and the structure–toxicity relationships, but they are separate models either predicting the structure–activity or the structure toxicity. Therefore, this QSAR model is not suitable for predicting the toxicity of the compounds. Another QSAR model for toxicity is required.

**Conclusion**

With the 15 anti-haemozoin compounds, the satisfactorily satisfactory 2D-QSAR model using PLS method was generated after removing the outliers. Five two-dimensional descriptors of the training set were selected: atom count (a_ICM); adjacency and distance matrix descriptor (GCUT_SLOGP_2: the third GCUT descriptor using atomic contribution to logP; average total charge sum (h_pavgQ) in pKa prediction (pH = 7); a very low negative partial charge, including aromatic carbons which have a heteroatom-substitution in “ortho” position (PEOE_VSA-0) and molecular descriptor (rsynth: estimating the synthesizability of molecules as the fraction of heavy atoms that can be traced back to starting material fragments resulting from retrosynthetic rules), respectively. The interpretation of the developed model suggests that the anti-malarial activity of haemozoin inhibitors increases with molecules having higher average total charge sum (h_pavgQ) in pKa prediction (pH = 7). The QSAR model also highlights that the descriptor using atomic contribution to logP or the distance matrix descriptor (GCUT_SLOGP_2), and structural component of the molecules, including topological descriptors does make for better anti-malarial activity.

**References**

1. WHO. World malaria report 2018. Geneva, World Health Organization, 2018.
2. Murray MC, Perkins ME. Chemotherapy of malaria. Annu Rep Med Chem. 1996;31:141–50.
3. Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet. 2004;363:1017–24.
4. Posner GH, Maxwell JP, O’Dowd H, Krasavin M, Xie S, Shapiro TA. Anti-malarial sulfide, sulfone, and sulfonamide trioxanes. Bioorg Med Chem. 2000;8:1361–70.
5. Ryckebeusch A, Deprez-Poulain R, Debeuf-Fontaine MA, Vandaele R, Mouray E, Grellier P, et al. Synthesis and antimalarial evaluation of new 1,4-bis(3-aminopropyl)piperazine derivatives. Bioorg Med Chem Lett. 2003;13:3783–7.
6. Agrawal VK, Srivastava R, Khadikar PV. QSAR studies on some antimalarial sulfonamides. Bioorg Med Chem. 2001;9:3287–93.
7. Sondo P, Derra K, Lefevre T, Diallo-Nakanabo S, Tarnagda Z, Zampa O, et al. Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Sci Rep. 2019;9:127.
8. Ojha PK, Roy K. The current status of antimalarial drug research with special reference to application of QSAR models. Comb Chem High Throughput Screening. 2015;18:91–128.
9. Yousefinejad S, Mahboubifar M, Eskandari R. Quantitative structure-activity relationship to predict the anti-malarial activity in a set of new imidazolopiperazines based on artificial neural networks. Malar J. 2019;18:310.
10. Ojha PK, Kumar V, Roy J, Roy K. Recent advances in quantitative structure-activity relationship models of antimalarial drugs. Expert Opin Drug Discov. 2021;1:1–37. (online ahead of print)
11. Joshi N, Hada R, Gupta S, Khan J, Dobrovolski J, Dhar PK, et al. Highly potent anti-malarial activity of benzopyran(4,3-b)benzopyran derivatives and in silico interaction analysis with putative target Plasmodium falciparum lactate dehydrogenase. J Biomol Struct Dyn. 2021:1–16. (online ahead of print)
12. Ferreira LT, Borba JVB. QSAR-based virtual screening of natural products database for identification of potent antimalarial hits. Biomolecules. 2021;11:459.
13. Hadni H, Elhallamou M. 2D and 3D-QSAR, molecular docking and ADMET properties in silico studies of azaaaurones as antimalarials. N J Chem. 2020;44:653–65.
14. Vyas VK, Panikh H, Ghate M. 3D QSAR studies on S-(2-methylbenzimidazol-1-yl)-N-alkylthiophene-2-carboxamide derivatives as P. falciparum dihydroorotate dehydrogenase (PDHODH) inhibitors. Med Chem Res. 2013;22:2235–43.
15. Cheng F, Shen J, Luo X, Zhu W, Gu J, Ji R, et al. Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artesinin analogues. Bioorg Med Chem. 2002;10:2883–91.
16. Katritzky AR, Kulshyn OV, Stoyanova-Slavova I, Dobrechev DA, Kuanar M, Fara DC, et al. Antimalarial activity: a QSAR modeling using CODESSA PRO software. Bioorg Med Chem. 2006;14:2333–57.
17. Cardoso FJ, de Figueredo AF, da Silva LM, de Miranda RM, de Almeida RC, Pinheiro JC. A study on antimalarial artesinin derivatives using MEP maps and multivariate QSAR. J Mol Model. 2008;14:39–48.
18. Tam DNH, Tawfik GM, El-Qushayri AE, Mehyar GM, Istanbully S, Karimzadeh S, et al. Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds. Malar J. 2020;19:298.
19. Huy NT, Chi PI, Nagai J, Dang TN, Mbanefo EC, Ahmed AM, et al. High-throughput screening and prediction model building for novel hemozoin inhibitors using physicochemical properties. Antimicrob Agents Chemother. 2017;61:e01607-e1616.
20. Mosaddeque F, Mizukami S, Kamel MG, Teklemichael AA, Dat TV, Mizuta S, et al. Prediction model for antimalarial activities of hemozoin inhibitors by using physicochemical properties. Antimicrob Agents Chemother. 2018;62:e02424-e2517.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.